Elutia Q3 2026 net loss narrows 67% year over year to $1.3 million
ELUT•Elutia’s third-quarter net loss narrowed 67% year over year to $1.3 million, while net sales rose 20% to $1.1 million. The company raised $26 million without an equity offering and plans to submit NXT-41x to the FDA in the fourth quarter of 2026.
1. Quarterly results
Elutia’s third-quarter 2026 net loss narrowed 67% year over year to $1.3 million. Continuing operations’ net loss widened to $6.5 million, while discontinued operations swung to income of $5.2 million. Net sales rose 20% year over year to $1.1 million.
2. Funding and timeline
The company raised $26 million without an equity offering, with funding expected to last through NXT-41x’s full commercial launch in 2028. Elutia plans to submit NXT-41x to the FDA in the fourth quarter of 2026 and anticipates clearance in the first half of 2027.
